Literature DB >> 1227472

Lassa virus hepatitis. Observations on a fatal case from the 1972 Sierra Leone epidemic.

W C Winn, T P Monath, F A Murphy, S G Whitfield.   

Abstract

During a recent outbreak of Lassa fever in Sierre Leone, a 20-year-old woman developed an acute febrile disease with tonsillar exudates and hemorrhagic manifestations. Lassa virus was isolated in cell cultures from pharyngeal secretions and pleural fluid and was identified by complement fixation. Typical arenavirus particles were observed in these infected cell cultures. In a liver biopsy specimen, diffuse hepatocellular damage and focal necroses were evident, with a spectrum of liver cell change, ranging from slight vacuolizaiton to frank lysis. Virus was frequently observed in nearby extracellular spaces and was clearly associated with hepatocytes rather than sinusoidal cells. The demonstration for the first time of Lassa virus particules in human tissue provides direct evidence that the virus is responsible for the observed pathologic changes.

Entities:  

Mesh:

Substances:

Year:  1975        PMID: 1227472

Source DB:  PubMed          Journal:  Arch Pathol        ISSN: 0363-0153


  17 in total

1.  Lassa virus nucleoprotein mutants generated by reverse genetics induce a robust type I interferon response in human dendritic cells and macrophages.

Authors:  Xavier Carnec; Sylvain Baize; Stéphanie Reynard; Laure Diancourt; Valérie Caro; Noel Tordo; Michèle Bouloy
Journal:  J Virol       Date:  2011-08-31       Impact factor: 5.103

2.  Genomic profiling of host responses to Lassa virus: therapeutic potential from primate to man.

Authors:  Juan C Zapata; Maria S Salvato
Journal:  Future Virol       Date:  2015-03-13       Impact factor: 1.831

3.  Pathologic and virologic study of fatal Lassa fever in man.

Authors:  D H Walker; J B McCormick; K M Johnson; P A Webb; G Komba-Kono; L H Elliott; J J Gardner
Journal:  Am J Pathol       Date:  1982-06       Impact factor: 4.307

4.  Lassa virus infection in experimentally infected marmosets: liver pathology and immunophenotypic alterations in target tissues.

Authors:  Ricardo Carrion; Kathleen Brasky; Keith Mansfield; Curtis Johnson; Monica Gonzales; Anysha Ticer; Igor Lukashevich; Suzette Tardif; Jean Patterson
Journal:  J Virol       Date:  2007-04-04       Impact factor: 5.103

5.  Identification of cell surface molecules involved in dystroglycan-independent Lassa virus cell entry.

Authors:  Masayuki Shimojima; Ute Ströher; Hideki Ebihara; Heinz Feldmann; Yoshihiro Kawaoka
Journal:  J Virol       Date:  2011-12-07       Impact factor: 5.103

6.  Antibody to mouse alpha/beta interferon abrogates Pichinde virus-induced liver lesions in suckling mice.

Authors:  T Clark; I Gresser; C Pfau; J Moss; D Woodrow
Journal:  J Virol       Date:  1986-09       Impact factor: 5.103

7.  Early and strong immune responses are associated with control of viral replication and recovery in lassa virus-infected cynomolgus monkeys.

Authors:  Sylvain Baize; Philippe Marianneau; Philippe Loth; Stéphanie Reynard; Alexandra Journeaux; Michèle Chevallier; Noël Tordo; Vincent Deubel; Hugues Contamin
Journal:  J Virol       Date:  2009-03-18       Impact factor: 5.103

8.  Comparative pathology of Lassa virus infection in monkeys, guinea-pigs, and Mastomys natalensis.

Authors:  D H Walker; H Wulff; J V Lange; F A Murphy
Journal:  Bull World Health Organ       Date:  1975       Impact factor: 9.408

9.  T cell-dependence of Lassa fever pathogenesis.

Authors:  Lukas Flatz; Toni Rieger; Doron Merkler; Andreas Bergthaler; Tommy Regen; Mariann Schedensack; Lukas Bestmann; Admar Verschoor; Mario Kreutzfeldt; Wolfgang Brück; Uwe-Karsten Hanisch; Stephan Günther; Daniel D Pinschewer
Journal:  PLoS Pathog       Date:  2010-03-26       Impact factor: 6.823

10.  Human macrophages, but not dendritic cells, are activated and produce alpha/beta interferons in response to Mopeia virus infection.

Authors:  Delphine Pannetier; Caroline Faure; Marie-Claude Georges-Courbot; Vincent Deubel; Sylvain Baize
Journal:  J Virol       Date:  2004-10       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.